The Pharmaceutical Journal
Vol 273 No 7314 p279
28 August 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

NICE issues eczema guidance

Tacrolimus (Protopic) has been endorsed as an option for second-line treatment of moderate to severe atopic eczema in adults and children by the National Institute for Clinical Excellence. Pimecrolimus (Elidel) is also recommended for second-line treatment of eczema on the face and neck in children.

Both products should only be used for eczema that has not been controlled by topical corticosteroids or where there is serious risk of adverse effects from corticosteroid use. NICE has also issued guidance on how topical corticosteroids should be applied.

The guidance is available here and will be set out in more detail next week.